

November 10, 2025

To, To, **BSE Limited**, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai- 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE | | Series: EQ

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR")

This is in continuation to our disclosure dated November 5, 2025 in relation to the conference call to discuss the Un-audited financial results of the Company for the quarter and half year ended September 30, 2025, please find enclosed herewith the investor presentation made for the aforesaid call.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Encl.: a/a. Thanking You, For Camlin Fine Sciences Limited

Rahul Sawale Company Secretary & VP - Legal



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098. CIN: L74100MH1993PLC075361












INTEGRATING SOLUTIONS

ADDING VALUE

Investor Presentation – November 2025

Camlin Fine Sciences Limited



Safe Harbour



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Camlin Fine Sciences Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.


Q2 & H1FY26
Performance Highlights




Q2 & H1FY26 Operational Highlights




Revenue (Rs. In Mn)



EBITDA Margin %



EBITDA (Rs. In Mn)



PAT (Rs. In Mn)



Continued Operation

Discontinued Operation

Q2 & H1FY26 Highlights



From Continuing Operations


- Revenue in the quarter improves to Rs. 4,598 mn, a growth of 8.6%
- Revenue for Speciality Ingredients Straights grew, however demand remains sluggish with local competition on the horizon
- Blends business witnessed steady growth in key markets with impressive growth in CFS Vitafor
- Vanillin revenue grew by 41% despite channel stocks and tariff impact, however the realization were lower than expected which impacted the margins
- Employee cost increase due to emphasis on strengthening of Blends marketing team in key geographies which will bear fruit in the coming quarters
- Consequentially, adjusted EBITDA increased to Rs. 334 mn in the quarter from Rs. 190 mn in last quarter
- EBITDA margin stood at 7.3% in Q2FY26 (4.5% in Q1FY26)
- Losses of discontinued operations are as expected
- Substantial reduction in losses (before taxes) from continued business from Rs 43 mn to Rs 1mn
- Net Debt remains under control at Rs. 5,197 mn
- Outlook for remaining Financial Year
 - Blends business to grow at higher pace fueled by strong marketing team, deeper market penetration, encouraging orderbook visibility and Inorganic acquisition
 - Volume of Vanillin will remain on a growth path with margin improvement on tariff situation

Operational Revenue Breakup




From Continuing Operations


Specialty Ingredients (Rs. In Mn) (Straights)




Specialty Ingredients (Rs. In Mn) (Value added blends)




Total Specialty Ingredients (Rs. In Mn)




Performance Chemicals (Rs. In Mn)



Aroma Ingredients (Rs. In Mn)



Total Revenue Breakup (%)*



Specialty Ingredients (Value Added Blends)

Performance Chemicals


Aroma Ingredients

Regional Highlights





From Continuing Operations


CFS India (Rs. In Mn) 4,355 4,088 2,440 2,269 1,914 Q2 FY25 Q1 FY26 Q2 FY26 H1 FY25




CFS Brazil (Rs. In Mn)







CFS North America (Rs. In Mn)







7

Consolidated Profit & Loss Statement



	From Continuing Op	perations			
Particulars (Rs. In Mn)	Q2 FY26	Q2 FY25	Q1 FY26	H1FY26	H1FY25
Revenue from Operation	4,598.3	4,173.2	4,235.5	8,833.8	7,981.7
Raw material consumption	2,467.2	2,157.7	2,368.8	4,836.0	4,198.9
Employee Cost	602.9	479.9	595.7	1,198.6	942.5
Other expenses	1,194.1	1,020.7	1,080.7	2,274.8	1,933.7
EBITDA	334.1	514.9	190.3	524.4	906.7
EBITDA Margins (%)	7.27%	12.34%	4.49%	5.94%	11.36%
Adjusted EBITDA*	334.1	514.9	190.3	524.4	906.7
Adjusted EBITDA Margins (%)	7.27%	12.34%	4.49%	5.94%	11.36%
Other Income	45.9	113.1	85.6	131.5	29.0
Depreciation	188.3	165.1	169.2	357.5	310.6
Finance cost	189.1	263.2	158.3	347.4	495.9
Exceptional Item	0.0	42.2	0.0	0.0	42.2
Share of profit / (loss) of associate	-3.6	5.1	8.9	5.3	5.1
PBT	-0.9	162.6	-42.6	-43.6	92.1
Tax	59.1	-262.0	-0.1	59.0	-150.3
PAT	-60.0	424.6	-42.5	-102.6	242.4
PAT Margin (%)	-1.31%	10.17%	-1.00%	-1.16%	3.04%
	From Discontinued O	perations#			
PBT from discontinued operation	-89.5	-1,585.7	-64.3	-153.7	-1,749.9
Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0
PAT including Discontinued Operations	-149.5	-1,161.1	-106.8	-256.3	-1,507.6

Consolidated Balance Sheet



Mar - 25

5,925.6

97.3

513.5

474.7

102.3

21.6

229.7

144.0

650.3

187.3

57.7 **8,404.0**

5,268.6

380.1

3,282.2 1,040.7

497.3

100.0

23.8

1,241.2

0.0

11,833.9

20,237.92

Particulars (Rs. In Mn)	Sept - 25	Mar - 25	Particulars (Rs. In Mn)	Sept - 25
Equity	3cpt 23	10101 20	Non-Current assets	
Equity Share Capital	188.0	187.9	Property, Plant and Equipment	5,849.1
• • •	8,707.7		Capital Work-In-Progress	146.5
Other Equity	·	8,828.8	Right use of assets	451.0
Minority interest	-294.5	-268.9	Goodwill	474.7
Total Equity	8,601.2	8,747.8	Other Intangible Assets	208.4
Non-Current Liabilities			Intangible assets under development	0.0
Financial Liabilities			Investment Property	21.6
Borrowings	2,900.7	2,683.0	Financial Assets	
Lease Liabilities	192.8	251.4	Investments	289.2
Other Liabilities	5.7	3.8	Other Financial Assets	170.7
Provisions	66.0	54.8	Deferred tax assets	736.9
Deferred Tax Liabilities (Net)	37.4	33.1	Income Tax Assets	285.2
Other non-current liabilities	1.8	1.8	Other Non-Current Assets	66.3
			Total Non-Current Assets	8,699.5
Total Non-Current Liabilities	3,204.3	3,028.0	Current Assets	
Current Liabilities			Inventories	5,309.5
Financial Liabilities			Financial Assets	
Borrowings	3,516.6	3,773.4	Investments	398.2
Lease Liabilities	107.0	105.2	Trade Receivables	3,257.7
Trade Payables	4,034.4	3,772.2	Cash and Cash Equivalents	874.4
Other Financial Liabilities	604.5	518.9	Bank Balances	325.9
Other Current Liabilities	146.7	159.4	Loans	100.9
Provisions	132.7	110.8	Other Financial Assets	29.3
	21.8	22.1	Other Current Assets	1,374.0
Current tax liabilities (Net)			Assets held for sale	0.0
Total Current Liabilities	8,563.8	8,462.1	Total Current Assets	11,669.8
Total Equity and Liabilities	20,369.3	20,237.9	Total Assets	20,369.3



Company Overview



Company Overview





100+

Range of Diversified Products offerings



1,250+

Base of Satisfied Customers Worldwide



Preferred Partner

For Customized Shelf-Life Solutions



High Quality & Wide Range

Vanillin Manufacturer



Among Global Leaders


in the Manufacturing of Antioxidants



49,000+


Led by Integrated Global Production Capacity

FY25 Revenue Mix*# ₹ 16,319 mn



Catering Diverse Industries

Food & Beverage	Animal Nutrition	Pet Food	Flavours & Fragrances	Dietary Supplements
Pharmaceuticals & Pharma Intermediates	Petrochemicals	Dyes & Pigments	Polymers	Agrochemicals
Poultry & Livestock	Bio-Fuels	Aquaculture & Fishmeal	Personal Care & Home Care	Incense Sticks



Global Footprint



7


Global Manufacturing Facilities

6
Application
Laboratories

80+

Presence in Countries

R&D Centres



Product Highlights



	FY25 Sales%*#	Key Products	End User Industries	Key Brands
→ Straights Specialty	23%	 TBHQ BHA Ascorbyl palmitate (ASP) 	 Pet Food Livestock Nutrition Food & Beverages Fish Meal Animal Feed Mills Biodiesel Aquaculture & Fishmeal Rendering 	NaSure Extending Shelf Life Naturally Specifical Specification of the Naturally Specification of the Natural Specification of
Value added Blends 54%	 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends) 	 These formulations are specifically tailored to meet the diverse needs of the industry Aim to increase focus on high-value blends and additives 	Xtendra shelf life solutions BIOSUS DHA CHAPTIT PURP SIGNER CHAPTIT PU	
Performance Chemicals	12%	 HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB 	 Petrochemicals Dyes & Pigments Agrochemicals Polymers Printing Inks 	Dinamic Performance Chemicals
Aroma Ingredients	11%	› Vanillin, Ethyl Vanillin and Vanillin ex- clove (adorr™)	 > Food & Beverages > Pharmaceutical > Incense sticks > Animal Feed 	ad s (f

Innovation at Work







Powered by Vertical Integration


- Efforts in both organic and inorganic expansions, showcases company's commitment to fortifying position in the market
- Strategic focus on captive consumption ensures utilization of raw materials for downstream products
- Strategic forward integration into Blends and Vanillin swings company's business model to high-value additives / solutions

Process Optimization Initiatives

- Vanillin Production Optimization: Continuous improvement at Dahej plant, refining processes and setting a future oriented strategic direction
- **Animal Nutrition:** Dedicated to the continuous improvement and development of products using technical expertise of CS Dresen and customizing products to suit the market needs, anticipated for the upcoming year
- Quality Enhancements: Focused on Analytical and Quality Enhancements through Instrumental Analysis and Method Development, which play critical roles in ensuring the integrity and efficacy of our products

Product Development:

- **High-Quality Hydroquinone**: Developed a high-quality specialized grade for Hydroquinone, leading to the crucial phase of conducting plant trials
- Catechol Downstream Products: Development of new downstream products in progress
- Antioxidant Innovations: Continuous development and enhancement of quality antioxidants, tailored specifically for discerning customers. These products have smoothly transitioned from R&D to full scale production and have already made market debut
- Naturals & Emulsifiers: Newest offerings include emulsifier-based ingredients designed to enhance texture, consistency, mouthfeel, appearance, process efficiency and yield for diverse range of food industry applications
- Upcoming Products: FY26 will see the commercialization of many new speciality ingredients.



ESG



Environment



- Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal
- · Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy
- Constantly seeking new ways to promote eco-friendliness
- Specifically target food segments that require improved shelf life
- Offer solutions for improving nutrition, health, and hygiene in livestock, resulting in enhanced Food Conversion Ratio (FCR) and overall animal performance

Social



- Supported organizations such as Akhil Bharatiya Vanavasi Kalyan Ashram & Institute of Chemical Technology to improve quality of life and sustain humanity
- Employee Wellness Initiatives to provides nutritionist consulting, diet planning, gym access, and frequent health monitoring to boost employee wellness

Governance



- Have a Governance Board that comprises highly skilled and visionary leaders from diverse backgrounds, bringing a wealth of technical and business expertise to the table
- Actively participate in brainstorming sessions with the aim of formulating comprehensive strategies and policies

Board Of Directors





Ashish Dandekar Chairman & Managing Director

- Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing
- Holds a BA in Economics and Management studies from Temple University, USA



Amol Shah Independent Director

- Managing Director of the MJ Group with over three decades of experience covering human healthcare, F&F compounds, plant protection, and water treatment chemicals
- Holds an MBA from the University of Southern California and a Bachelor's in Engineering from the University of Kent



Nirmal Momaya Managing Director

- Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy
- He has been instrumental in providing strategic guidance & direction to the company on all significant business matters



Mahabaleshwar Palekar Independent Director

- Over three decades of experience with corporates in India and MNCs
- > Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India



Arjun Dukane Executive Director-Technical

- Chemical Engineer with over three decades of experience in the chemical industry
- Has been associated with CFS for more than 15 years



Joseph Conrad D'souza Independent Director

- Erstwhile Member of Executive Management and Ex-Chief Investor Relations Officer of HDFC Ltd
- Holds an M.com from Mumbai University and an MBA from South Gujarat University



Harsha Raghavan Non-Executive Non-Independent Director

- Managing Partner of Convergent Finance LLP and exfounding MD & CEO of Fairbridge Capital (a Fairfax Company)
- Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley



Pradip Kanakia Independent Director

- Qualified Chartered Accountant (both England, Wales and India) with over three decades of experience
- Held leadership position in PWC & KPMG, leveraging his expertise in strategy, transformation, performance management, accounting, auditing, reporting, controls, compliance & governance



Anagha Dandekar Non-Executive Non-Independent Director

- President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories
- Holds an MBA in Finance from the University of South Carolina, USA



Abeezar Faizullabhoy Independent Director

- Senior Partner at Argus Partners (Solicitors & Advocates) Mumbai and ex-partner of J Sagar Associates
- Holds Bachelor of Law from University of Mumbai and a Qualified Solicitor from Bombay incorporated law society
- Was previously on Board of CFS for 13 years till 2019, His immense experience in the Corporate commercial, litigation, M&A



Jens Van
Nieuwenborgh
Non-Executive
Non-Independent
Director

- Board member of several companies across India and Europe, with extensive experience in business administration, finance, and operations
- Holds an MBA from Harvard University and a Master's in Science from Ghent University, Belgium.



Radhika Dudhat Independent Director

- Over three decades of experience with corporates in India and MNCs
- Partner with Shardul Amarchand Mangaldas & Co. and has worked on a wide range of transactional, regulatory and legal risk management advisory
- Holds degrees in Life Sciences and Law from the University of Bombay, with postgraduate studies at Cambridge and Harvard.

Senior Management Team




Ashish Dandekar Chairman & Managing Director	 Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing Holds a BA in Economics and Management studies from Temple University, USA
Nirmal Momaya Managing Director	 Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy He has been instrumental in providing strategic guidance & direction to the company on all significant business matters
Arjun Dukane Executive Director-Technical	 Chemical Engineer with over three decades of experience in the chemical industry Has been associated with CFS for more than 15 years
Santosh Parab Chief Financial Officer	 Over two decades of experience working auditing profession Previously worked at B.K. Khare & Co, an Indian accounting firm Qualified Chartered Accountant with a Bachelor's degree in commerce Associated with CFS for more than 9 years
Nilesh Jadhav Chief Operating Officer	 Chemical Engineer with around three decades of experience in the chemical industry including heading multilocational manufacturing sites Previously worked at Balaji Amines, Deepak Fertilizers & Petrochemicals, Essar Refinery & Schenectady Executive Management from IIM Bangalore and Piping Engineering from IIT Powai
Eric Santos Vice President - Aroma Ingredients	 Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. Holds a Bachelor's degree in chemistry
Massimo Cupello Head - Italy operations	 Over three decades of experience in varied industries including food chocolate and private equity Previously worked at Ferrero Chocolate, Unopiu (Sinergo & CCP) in Europe Holds an MBA in International Business and a Bachelor's degree in Science
Jose Arturo Paulin Head - Mexico operations	 Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) Previously worked at Trouw Nutrition and Kemin Inc in Mexico Qualifed agriculture engineer
Jennifer Igou Head - USA operations	 Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids Previously worked at Kemin Inc. USA & FMC Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine




Historical Financial Highlights




Revenue (Rs. In Mn)




EBITDA (Rs. In Mn)



PAT (Rs. In Mn)



Net Debt to Equity (x)



Net Debt to EBITDA (x)




Continued Operation

Discontinued Operation


Operational Revenue Break-Up




Specialty Ingredients (Rs. In Mn) (Straights)




Performance Chemicals (Rs. In Mn)




Specialty Ingredients (Rs. In Mn) (Value added blends)




Aroma Ingredients (Rs. In Mn)



Total Specialty Ingredients (Rs. In Mn)



Total Revenue Breakup (%)*




Specialty Ingredients (Straights) Specialty Ingredients (Value Added Blends)

Performance Chemicals Aroma Ingredients


Regional Highlights




CFS India (Rs. In Mn)




CFS Mexico (Rs. In Mn)




CFS Europe (Rs. In Mn)



CFS Brazil (Rs. In Mn)



CFS North America (Rs. In Mn)





Thank You!



Camlin Fine Sciences Ltd.

CIN - L74100MH1993PLCO75361 Santosh Parab- CFO Email - <u>santosh.parab@camlinfs.com</u> www.camlinfs.com

$SGA^{\underline{\mathtt{Strategic\ Growth\ Advisors}}}$

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285 Shrikant Sangani / Shaily Patwa Email <u>- shrikant.sangani@sgapl.net / shaily.p@sgapl.net</u> Mobile No - 9619595686 / 9819494608 www.sgapl.net

